OAK: OS in PDL1 subgroups
Atezolizumab
Docetaxel
IC0 and TC1/2/3
subgroup
13.2 months
(7.8–20.5)
12.0 months
(3.7–14.7)
HR 0.72
(95% CI 0.36–1.45)
IC1/2/3 and TC0
subgroup
14·3 months
(10·6–18·4)
9·8 months
(7·3–13·7)
HR 0.73
95% CI 0.52–1.02)
Rittmeyer. Lancet 2016
